人肝素酶RNA干扰对HepG2肝癌细胞生物学行为的影响
摘要
研究背景及目的
恶性肿瘤是当前严重影响人类健康的最重要的疾病之一。而肿瘤的侵袭和转移是导致肿瘤患者死亡的主要原因。肿瘤的早期诊断和早期治疗固然是肿瘤患者获得长期生存的主要途径,但许多就诊的患者多已发生转移,而常规的手术和放、化疗疗效有限。如何有效延长这类患者的生存期显得尤为重要。
肝素酶(Heparanase,Hpa)是目前发现的唯一能降解细胞外基质(Extracellular matrix,ECM)及基底膜(Base memebrance,BM)中乙酰肝素蛋白多糖(heparan sulfateproteoglycans,HSPG)的内源性糖苷内切酶。在正常组织中除淋巴细胞、骨髓等呈低表达外,在正常成熟的非免疫组织中(如心、肺、肝脏、骨骼肌及胰腺等)均不表达,但是在几乎所有的转移性恶性肿瘤细胞中普遍存在。目前的研究表明,肝素酶在诱导肿瘤血管生成、促进肿瘤侵袭和转移方面具有重要作用,而抑制肝素酶的表达可明显抑制肿瘤的增殖及转移。因此肝素酶作为一种肿瘤基因治疗的靶点已经受到越来越多的关注。
RNA干扰(RNA interference,RNAi)是指小分子双链RNA(siRNA)转录后基因沉默。siRNA主要通过特异地与序列互补的mRNA结合,并促使其降解。RNAi技术近年来发展非常迅速,尤其是在2001年《Science》杂志首次报道siRNA可以诱导哺乳动物细胞特异性基因沉默后,RNAi逐渐成为生物医学研究中的一项重要的实验工具。目前RNAi技术已基本替代传统的反义核酸技术诱导特异性基因沉默而广泛应用到基因功能鉴定、基因表达转录后调控等热门领域,并为多种疾病的基因治疗提供了新的思路。
基于以上分析,本实验拟通过RNAi技术诱导Hpa在HepG2肝癌细胞中沉默,并研究沉默Hpa后的HepG2细胞在肿瘤的生长、侵袭等各方面的变化情况,为Hpa作为肿瘤基因治疗的靶点提供理论依据。
研究方法
1.通过Genebank找到人肝素酶mRNA序列,应用网络在线工具设计3条干扰序列,经BLAST设计一组无关序列为阴性对照序列;设计包含干扰序列及无关序列的dsDNA并进行生物合成;双酶切pGenesil-1质粒:将合成的dsDNA克隆至酶切质粒;测序鉴定后进行质粒抽提及纯化。
2.培养HepG2细胞,采用脂质体法将各重组干扰质粒稳定转染至HepG2细胞:G418抗性筛选3周;从各组细胞中挑取单克隆扩大培养。
3.采用Real Time RT-PCR和Western blot分别检测干扰及未干扰的HepG2细胞肝素酶的表达,筛选有效的干扰序列。
4.采用不同的实验技术检测肝素酶RNA干扰后HepG2细胞增殖能力、细胞周期、克隆形成能力、侵袭能力及体内成瘤能力的变化。
实验结果
1.通过www.genscript.com网站的Online tools找到三条肝素酶干扰序列,分别为:No.1(1214-1232):5′-GGCTATCTCTTCTGTTCAA-3′,No.2(167-185):5′-TCCTGTCCGTCACCATrGA-3′,No.3(611-629):5′.CTCAGTTGC TCC TGG ACTA-3′,及阴性对照序列5′.ACTACCGTTGTATAGGTGT-3′:并成功将包含各干扰序列及阴性对照序列的dsDNA克隆至质粒pGenesil-1,经测序鉴定后,证实所连入的序列与设计序列一致,分别命名为pGenesil-1/Hpa/siRNA-1、pGenesil-1/Hpa/siRNA-2、pGenesil-1/Hpa/siRNA-3、pGenesil-1/Hpa/siRNA-N。
2.采用脂质体法将上述各组干扰质粒成功转染至HepG2肝癌细胞当中,经G418抗性筛选后,得到阳性克隆:扩大培养后各细胞株分别命名为HepG2/RNAi/1-1、HepG2/RNAi/2-2、HepG2/RNAi/3-1、HepG2/RNAi/3-3、HepG2/RNAi/N。
3.Real Time RT-PCR结果表明,干扰组HepG2/RNAi/1-1、HepG2/RNAi/2-2及HepG2/RNAi/3-3中Hpa在mRNA表达水平明显下调,而HepG2/RNAi/3-1中的Hpa表达与阴性对照组和HepG2组无差别;Westem blot检测结果表明HepG2/RNAi/1-1与HepG2/RNAi/3-3两组中Hpa蛋白表达水平较HepG2组和HepG2/RNAi/N组显著下调,抑制效率分别达到57%、71%。
4.采用Western blot检测不同代数干扰细胞肝素酶的表达,结果表明,在10代以前,Hpa/siRNA-1和Hpa/siRNA-3可以有效抑制HepG2肝癌细胞肝素酶蛋白的表达。
5.MTT实验表明HepG2/RNAi/1-1与HepG2/RNAi/3-3组细胞增殖能力明显低于HepG2组和HepG2/RNAi/N组;平皿克隆形成实验表明HepG2/RNAi/1-1与HepG2/RNAi/3-3组单个细胞形成克隆的能力与HepG2组和HepG2/RNAi/N组相比显著降低(34±4,26±5 vs 138±7,123±22,p＜0.05);流式细胞生长周期实验表明,与HepG2和HepG2/RNAi/N细胞相比,HepG2/RNAi/1-1与HepG2/RNAi/3-3 Go/G1期细胞比例增加,而S期细胞比例下降;Transwell体外侵袭实验表明,HepG2/RNAi/1-1与HepG2/RNAi/3-3细胞穿膜数较HepG2和HepG2/RNAi/N细胞穿膜数明显减少(85.1±9.1±78.1±10.4 VS182.2±9.7,183.5±9.3,p＜0.05);裸鼠成瘤实验显示,HepG2、HepG2/RNAi/N细胞成瘤率为100%,虽然HepG2/RNAi/1-1细胞成瘤亦为100%,但裸鼠皮下肿瘤体积较HepG2、HepG2/RNAi/N细胞明显缩小(0.099±0.030 vs 0.585±0.135,0.690±0.099,p＜0.01),而HepG2/RNAi/3-3细胞裸鼠皮下未见肿瘤形成。
结论
1.通过生物信息学技术,选取3条人肝素酶RNA干扰序列及1条阴性对照序列;通过基因重组技术,成功构建3种肝素酶RNAi载体及阴性对照载体:通过脂质体转染及G418抗性筛选,成功筛选出不同载体的抗性克隆;通过Realtime Time PCR和Westernblot技术,成功筛选出肝素酶有效干扰序列:即No.1(1214.1232)5′-GGCTATCTCTTCTGTTCAA-3′,No.3(61l-629)5′-CTCAGTTGCTCCTGGACTA-3′;并确定在10代以前,上述干扰序列可以有效地抑制HepG2肝癌细胞肝素酶的表达。
2.体外及体内实验证实,经过有效干扰后的HepG2肝癌细胞在细胞生长速度、单个细胞克隆形成能力、体外侵袭能力以及裸鼠皮下成瘤能力等方面均较HepG2细胞和阴性对照组显著下降。
以上研究表明,我们所筛选的人肝素酶干扰序列能有效抑制肝癌的增殖、侵袭以及成瘤能力,为肝素酶RNA干扰在中晚期肝癌及其他肿瘤中的治疗作用提供了理论依据。
Background and Objective
Malignant tumor is one of the most severe deseases that are threatening human health. Tumor invasion and metastasis are main causes leading to patients' death.Although early diagnosis and treatment would be the best way for patients obtaining long term survival, many patients are found to be metastasized and with little hope on surgery,chemotherapy and radiotherapy.Hence how to last the survival time of these patients is becoming an ever important goal.
Heparanase(Hpa)is the only endogenous endo-glycosidase found by now that is able to degradate heparan sulfate proteoglycans(HSPG) contained in extracellular matrix(ECM) and base memebrance(BM).In normal cells,except lymphocyte and bone marrow cells, heparanase is not expressed in most mature nonimmune tissue(such as heart,lung,liver, skeletal muscle and pancreas).However,it exists in almost all metastatic malignant tumor cells.Studies have shown that down-regulating expression of heparanase could obviously inhibit proliferation and metastasis of tumor cells.Heparanase is gaining more and more attention as a new target for tumor gene therapy.
RNA interference(RNAi) is gene silencing after the transcription of micromolecule double strands RNA(siRNA).siRNA selectively combines with it's complementary mRNA and induces it's degradation.The technology of RNAi has developed very fast recently.Specially after the report,on 2001 Science,of siRNA successfully inducing selective mammalian cell gene silencing,RNAi gradually becomes an important tool for biomedical research.Now RNAi technology has been vastly use in many hot field such as gene function test,post-transcriptional control of gene expression,replacing the conventional antisense nucleic acids method inducing specific gene silencing.It provides a new possibility of gene therapy for many kinds of desease.
Based on above analysis,this study uses RNAi technology to induce Hpa silencing in liver cancer cell line HepG2,investigating the Hpa silenced HepG2 status on tumor growth, invasion and so on,providing theoretical basis for target choosing of tumor gene therapy.
Method
1.Heparanase mRNA sequence is available in Genebank.We selected 3 interference sequences through on line design tool in web site,and a group of independence sequence by BLAST as negative control group.We further designed dsDNA including interference sequences and independence sequence for synthesis.Then double restricted enzyme digested pGenesil-1 was ligated with synthesized dsDNA.After being verified by sequencing we had it amplified and extracted.
2.HepG2 liver cancer cells were stablely transfected with each recombinant interference plasmid by DOTAP lipofection method.After 4 weeks of G418 selection,drug resistant clones were picked from each group for amplified culturing and were named as: HepG2/RNAi/N,HepG2/RNAi/1-1,HepG2/RNAi/2-2,HepG2/RNAi/3-1 and HepG2/RNAi/3-3,respectively.
3.Real Time RT-PCR and Western blot were carried out to screen effective interference sequences.
4.Changes of biological behaviour of HepG2 after heparanase RNA interference were investigated respectively on proliferation,cell cycle distribution,clone formation,invasion and tumorigenesis in nude mice.
Result
1.Three interference sequences were determined by online tools of www. genscript.com.They are:No.1(1214-1232):5' -GGCTATCTCTTCTGTTCAA-3',No.2 (167-185):5' -TCCTGTCCGTCACCATTGA-3',No.3(611-629):5' -CTCAGTTGCT CCTGGACTA-3',and negative control sequence 5' -ACTACCGTTGTATAGGTGT-3'; dsDNA that including interference and control sequences were successfully cloned into pGenesil-1 plasmid and confirmed correct by sequencing.These plasmids were named as pGenesil-1/Hpa/siRNA-1,pGenesil-1 /Hpa/siRNA-2,pGenesil-1/Hpa/siRNA-3 and pGenesil-1/Hpa/siRNA-N,respectively.
2.Each group of recombinant interference plasmids was transfected into HepG2 cells by DOTAP lipofection method.After 3 weeks of G418 selection,drug resistant clones were picked and named as HepG2/RNAi/1-1,HepG2/RNAi/2-2,HepG2/RNAi/3-1, HepG2/RNAi/3-3 and HepG2/RNAi/N cells respectively.
3.Real Time RT-PCR result showed that compared with HepG2 and HepG2/RNAi/N cells,mRNA level of Hpa was significantly down-regulated in the group of HepG2/RNAi/1-1,HepG2/RNAi/2-2 and HepG2/RNAi/3-3 cells except HepG2/RNAi/3-1 cells.Western blot result showed that Hpa protein level in HepG2/RNAi/1-1 and HepG2/RNAi/3-3 was significantly decreased compared with HepG2 and HepG2/RNAi/N cells.The inhibiting rate of heparanase protein was 57%and 71%respectively.This results confirm that sequence 5'- GGCTATCTCTTCTGTTCAA-3'(1214-1232) and 5'-CTCAG TTGCTCCTGGACTA-3'(611-629) are the effective interference sequences of heparanase.
4.Western blot testing various generations of interfered cells for heparanase protein level showed that before the 10th generation,No.1(1214-1232) and No.3(611-629) interference sequences could effectively inhibit expression of heparanase protein.
5.MTT result showed that cell proliferation ability of HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells was significantly lower than that of HepG2 and HepG2/RNAi/N cells.Plate clone formation experiment demonstrated that single cell clone formation capacity of HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells was obviously lower than that of HepG2 and HepG2/RNAi/N cells(34±4,26±5 vs 138±7,123±22,p＜0.05).Flow cytometry demonstrated that No.1(1214-1232) and No.3(611-629) interference sequence could increase HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells arresting in G_0/G_1 and decrease proliferative index(PI) of HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells.Transwell in vitro invasion experiment showed that penetrated cell number in HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells was much lower than in HepG2 and HepG2/RNAi/N cells(85.1±9.1, 78.1±10.4 vs 182.2±9.7,183.5±9.3,p＜0.05).Tumorigenesis in nude mice experiment demonstrated that HepG2 and HepG2/RNAi/N cells had a tumor formation ratio of 100%. Although HepG2/RNAi/1-1 cells also had a tumor formation ratio of 100%,but its subcutaneous tumor volume is much smaller than of HepG2 and HepG2/RNAi/N cells (0.099±0.030 vs 0.585±0.135,0.690±0.099,p＜0.01),while no subcutaneous tumor formed in group of HepG2/RNAi/3-3 cells.
Conclusion
1.Through bioinformatics technology,we choose three heparanase RNA interference sequences and a negative control sequence.We successfully construct three heparanase RNAi plasmids which are then stablely transfected into HepG2 liver cancer cells.Drug resistant clones are picked out after G418 selection for 4 weeks.By realtime time RT-PCR and Western blot,we successfully screened that 5'-GGCTATCT CTTCTGTTCAA-3' (1214-1232) and 5'-CTCAGTTGCTCCTGGACTA-3'(611-629) are the effective interference sequences of heparanase.Western blot further confirms that before the 10th generation,above interference sequences could effectively inhibit expression of heparanase protein in HepG2 cells.
2.A serial of in vivo and in vitro study indicated that after effectively interfered by the above sequences,the cell growth velocity,single cell clone formation capacity,in vitro invasion capacity and tumorigenesis in nude mice are significantly decreased in HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells compared with HepG2 and HepG2/RNAi/N cells.
The above results suggest that the heparanase RNAi sequences we screened can effectively inhibit HepG2 liver cancer cells in proliferation,invasion,and tumorigenesis in nude mice.The above heparanase RNAi sequences may therefore represent interesting candidates for the treatment of patients with advanced liver cancer and possibly also with other malignanices.
恶性肿瘤是当前严重影响人类健康的最重要的疾病之一。而肿瘤的侵袭和转移是导致肿瘤患者死亡的主要原因。肿瘤的早期诊断和早期治疗固然是肿瘤患者获得长期生存的主要途径,但许多就诊的患者多已发生转移,而常规的手术和放、化疗疗效有限。如何有效延长这类患者的生存期显得尤为重要。
肝素酶(Heparanase,Hpa)是目前发现的唯一能降解细胞外基质(Extracellular matrix,ECM)及基底膜(Base memebrance,BM)中乙酰肝素蛋白多糖(heparan sulfateproteoglycans,HSPG)的内源性糖苷内切酶。在正常组织中除淋巴细胞、骨髓等呈低表达外,在正常成熟的非免疫组织中(如心、肺、肝脏、骨骼肌及胰腺等)均不表达,但是在几乎所有的转移性恶性肿瘤细胞中普遍存在。目前的研究表明,肝素酶在诱导肿瘤血管生成、促进肿瘤侵袭和转移方面具有重要作用,而抑制肝素酶的表达可明显抑制肿瘤的增殖及转移。因此肝素酶作为一种肿瘤基因治疗的靶点已经受到越来越多的关注。
RNA干扰(RNA interference,RNAi)是指小分子双链RNA(siRNA)转录后基因沉默。siRNA主要通过特异地与序列互补的mRNA结合,并促使其降解。RNAi技术近年来发展非常迅速,尤其是在2001年《Science》杂志首次报道siRNA可以诱导哺乳动物细胞特异性基因沉默后,RNAi逐渐成为生物医学研究中的一项重要的实验工具。目前RNAi技术已基本替代传统的反义核酸技术诱导特异性基因沉默而广泛应用到基因功能鉴定、基因表达转录后调控等热门领域,并为多种疾病的基因治疗提供了新的思路。
基于以上分析,本实验拟通过RNAi技术诱导Hpa在HepG2肝癌细胞中沉默,并研究沉默Hpa后的HepG2细胞在肿瘤的生长、侵袭等各方面的变化情况,为Hpa作为肿瘤基因治疗的靶点提供理论依据。
研究方法
1.通过Genebank找到人肝素酶mRNA序列,应用网络在线工具设计3条干扰序列,经BLAST设计一组无关序列为阴性对照序列;设计包含干扰序列及无关序列的dsDNA并进行生物合成;双酶切pGenesil-1质粒:将合成的dsDNA克隆至酶切质粒;测序鉴定后进行质粒抽提及纯化。
2.培养HepG2细胞,采用脂质体法将各重组干扰质粒稳定转染至HepG2细胞:G418抗性筛选3周;从各组细胞中挑取单克隆扩大培养。
3.采用Real Time RT-PCR和Western blot分别检测干扰及未干扰的HepG2细胞肝素酶的表达,筛选有效的干扰序列。
4.采用不同的实验技术检测肝素酶RNA干扰后HepG2细胞增殖能力、细胞周期、克隆形成能力、侵袭能力及体内成瘤能力的变化。
实验结果
1.通过www.genscript.com网站的Online tools找到三条肝素酶干扰序列,分别为:No.1(1214-1232):5′-GGCTATCTCTTCTGTTCAA-3′,No.2(167-185):5′-TCCTGTCCGTCACCATrGA-3′,No.3(611-629):5′.CTCAGTTGC TCC TGG ACTA-3′,及阴性对照序列5′.ACTACCGTTGTATAGGTGT-3′:并成功将包含各干扰序列及阴性对照序列的dsDNA克隆至质粒pGenesil-1,经测序鉴定后,证实所连入的序列与设计序列一致,分别命名为pGenesil-1/Hpa/siRNA-1、pGenesil-1/Hpa/siRNA-2、pGenesil-1/Hpa/siRNA-3、pGenesil-1/Hpa/siRNA-N。
2.采用脂质体法将上述各组干扰质粒成功转染至HepG2肝癌细胞当中,经G418抗性筛选后,得到阳性克隆:扩大培养后各细胞株分别命名为HepG2/RNAi/1-1、HepG2/RNAi/2-2、HepG2/RNAi/3-1、HepG2/RNAi/3-3、HepG2/RNAi/N。
3.Real Time RT-PCR结果表明,干扰组HepG2/RNAi/1-1、HepG2/RNAi/2-2及HepG2/RNAi/3-3中Hpa在mRNA表达水平明显下调,而HepG2/RNAi/3-1中的Hpa表达与阴性对照组和HepG2组无差别;Westem blot检测结果表明HepG2/RNAi/1-1与HepG2/RNAi/3-3两组中Hpa蛋白表达水平较HepG2组和HepG2/RNAi/N组显著下调,抑制效率分别达到57%、71%。
4.采用Western blot检测不同代数干扰细胞肝素酶的表达,结果表明,在10代以前,Hpa/siRNA-1和Hpa/siRNA-3可以有效抑制HepG2肝癌细胞肝素酶蛋白的表达。
5.MTT实验表明HepG2/RNAi/1-1与HepG2/RNAi/3-3组细胞增殖能力明显低于HepG2组和HepG2/RNAi/N组;平皿克隆形成实验表明HepG2/RNAi/1-1与HepG2/RNAi/3-3组单个细胞形成克隆的能力与HepG2组和HepG2/RNAi/N组相比显著降低(34±4,26±5 vs 138±7,123±22,p＜0.05);流式细胞生长周期实验表明,与HepG2和HepG2/RNAi/N细胞相比,HepG2/RNAi/1-1与HepG2/RNAi/3-3 Go/G1期细胞比例增加,而S期细胞比例下降;Transwell体外侵袭实验表明,HepG2/RNAi/1-1与HepG2/RNAi/3-3细胞穿膜数较HepG2和HepG2/RNAi/N细胞穿膜数明显减少(85.1±9.1±78.1±10.4 VS182.2±9.7,183.5±9.3,p＜0.05);裸鼠成瘤实验显示,HepG2、HepG2/RNAi/N细胞成瘤率为100%,虽然HepG2/RNAi/1-1细胞成瘤亦为100%,但裸鼠皮下肿瘤体积较HepG2、HepG2/RNAi/N细胞明显缩小(0.099±0.030 vs 0.585±0.135,0.690±0.099,p＜0.01),而HepG2/RNAi/3-3细胞裸鼠皮下未见肿瘤形成。
结论
1.通过生物信息学技术,选取3条人肝素酶RNA干扰序列及1条阴性对照序列;通过基因重组技术,成功构建3种肝素酶RNAi载体及阴性对照载体:通过脂质体转染及G418抗性筛选,成功筛选出不同载体的抗性克隆;通过Realtime Time PCR和Westernblot技术,成功筛选出肝素酶有效干扰序列:即No.1(1214.1232)5′-GGCTATCTCTTCTGTTCAA-3′,No.3(61l-629)5′-CTCAGTTGCTCCTGGACTA-3′;并确定在10代以前,上述干扰序列可以有效地抑制HepG2肝癌细胞肝素酶的表达。
2.体外及体内实验证实,经过有效干扰后的HepG2肝癌细胞在细胞生长速度、单个细胞克隆形成能力、体外侵袭能力以及裸鼠皮下成瘤能力等方面均较HepG2细胞和阴性对照组显著下降。
以上研究表明,我们所筛选的人肝素酶干扰序列能有效抑制肝癌的增殖、侵袭以及成瘤能力,为肝素酶RNA干扰在中晚期肝癌及其他肿瘤中的治疗作用提供了理论依据。
Background and Objective
Malignant tumor is one of the most severe deseases that are threatening human health. Tumor invasion and metastasis are main causes leading to patients' death.Although early diagnosis and treatment would be the best way for patients obtaining long term survival, many patients are found to be metastasized and with little hope on surgery,chemotherapy and radiotherapy.Hence how to last the survival time of these patients is becoming an ever important goal.
Heparanase(Hpa)is the only endogenous endo-glycosidase found by now that is able to degradate heparan sulfate proteoglycans(HSPG) contained in extracellular matrix(ECM) and base memebrance(BM).In normal cells,except lymphocyte and bone marrow cells, heparanase is not expressed in most mature nonimmune tissue(such as heart,lung,liver, skeletal muscle and pancreas).However,it exists in almost all metastatic malignant tumor cells.Studies have shown that down-regulating expression of heparanase could obviously inhibit proliferation and metastasis of tumor cells.Heparanase is gaining more and more attention as a new target for tumor gene therapy.
RNA interference(RNAi) is gene silencing after the transcription of micromolecule double strands RNA(siRNA).siRNA selectively combines with it's complementary mRNA and induces it's degradation.The technology of RNAi has developed very fast recently.Specially after the report,on 2001 Science,of siRNA successfully inducing selective mammalian cell gene silencing,RNAi gradually becomes an important tool for biomedical research.Now RNAi technology has been vastly use in many hot field such as gene function test,post-transcriptional control of gene expression,replacing the conventional antisense nucleic acids method inducing specific gene silencing.It provides a new possibility of gene therapy for many kinds of desease.
Based on above analysis,this study uses RNAi technology to induce Hpa silencing in liver cancer cell line HepG2,investigating the Hpa silenced HepG2 status on tumor growth, invasion and so on,providing theoretical basis for target choosing of tumor gene therapy.
Method
1.Heparanase mRNA sequence is available in Genebank.We selected 3 interference sequences through on line design tool in web site,and a group of independence sequence by BLAST as negative control group.We further designed dsDNA including interference sequences and independence sequence for synthesis.Then double restricted enzyme digested pGenesil-1 was ligated with synthesized dsDNA.After being verified by sequencing we had it amplified and extracted.
2.HepG2 liver cancer cells were stablely transfected with each recombinant interference plasmid by DOTAP lipofection method.After 4 weeks of G418 selection,drug resistant clones were picked from each group for amplified culturing and were named as: HepG2/RNAi/N,HepG2/RNAi/1-1,HepG2/RNAi/2-2,HepG2/RNAi/3-1 and HepG2/RNAi/3-3,respectively.
3.Real Time RT-PCR and Western blot were carried out to screen effective interference sequences.
4.Changes of biological behaviour of HepG2 after heparanase RNA interference were investigated respectively on proliferation,cell cycle distribution,clone formation,invasion and tumorigenesis in nude mice.
Result
1.Three interference sequences were determined by online tools of www. genscript.com.They are:No.1(1214-1232):5' -GGCTATCTCTTCTGTTCAA-3',No.2 (167-185):5' -TCCTGTCCGTCACCATTGA-3',No.3(611-629):5' -CTCAGTTGCT CCTGGACTA-3',and negative control sequence 5' -ACTACCGTTGTATAGGTGT-3'; dsDNA that including interference and control sequences were successfully cloned into pGenesil-1 plasmid and confirmed correct by sequencing.These plasmids were named as pGenesil-1/Hpa/siRNA-1,pGenesil-1 /Hpa/siRNA-2,pGenesil-1/Hpa/siRNA-3 and pGenesil-1/Hpa/siRNA-N,respectively.
2.Each group of recombinant interference plasmids was transfected into HepG2 cells by DOTAP lipofection method.After 3 weeks of G418 selection,drug resistant clones were picked and named as HepG2/RNAi/1-1,HepG2/RNAi/2-2,HepG2/RNAi/3-1, HepG2/RNAi/3-3 and HepG2/RNAi/N cells respectively.
3.Real Time RT-PCR result showed that compared with HepG2 and HepG2/RNAi/N cells,mRNA level of Hpa was significantly down-regulated in the group of HepG2/RNAi/1-1,HepG2/RNAi/2-2 and HepG2/RNAi/3-3 cells except HepG2/RNAi/3-1 cells.Western blot result showed that Hpa protein level in HepG2/RNAi/1-1 and HepG2/RNAi/3-3 was significantly decreased compared with HepG2 and HepG2/RNAi/N cells.The inhibiting rate of heparanase protein was 57%and 71%respectively.This results confirm that sequence 5'- GGCTATCTCTTCTGTTCAA-3'(1214-1232) and 5'-CTCAG TTGCTCCTGGACTA-3'(611-629) are the effective interference sequences of heparanase.
4.Western blot testing various generations of interfered cells for heparanase protein level showed that before the 10th generation,No.1(1214-1232) and No.3(611-629) interference sequences could effectively inhibit expression of heparanase protein.
5.MTT result showed that cell proliferation ability of HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells was significantly lower than that of HepG2 and HepG2/RNAi/N cells.Plate clone formation experiment demonstrated that single cell clone formation capacity of HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells was obviously lower than that of HepG2 and HepG2/RNAi/N cells(34±4,26±5 vs 138±7,123±22,p＜0.05).Flow cytometry demonstrated that No.1(1214-1232) and No.3(611-629) interference sequence could increase HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells arresting in G_0/G_1 and decrease proliferative index(PI) of HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells.Transwell in vitro invasion experiment showed that penetrated cell number in HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells was much lower than in HepG2 and HepG2/RNAi/N cells(85.1±9.1, 78.1±10.4 vs 182.2±9.7,183.5±9.3,p＜0.05).Tumorigenesis in nude mice experiment demonstrated that HepG2 and HepG2/RNAi/N cells had a tumor formation ratio of 100%. Although HepG2/RNAi/1-1 cells also had a tumor formation ratio of 100%,but its subcutaneous tumor volume is much smaller than of HepG2 and HepG2/RNAi/N cells (0.099±0.030 vs 0.585±0.135,0.690±0.099,p＜0.01),while no subcutaneous tumor formed in group of HepG2/RNAi/3-3 cells.
Conclusion
1.Through bioinformatics technology,we choose three heparanase RNA interference sequences and a negative control sequence.We successfully construct three heparanase RNAi plasmids which are then stablely transfected into HepG2 liver cancer cells.Drug resistant clones are picked out after G418 selection for 4 weeks.By realtime time RT-PCR and Western blot,we successfully screened that 5'-GGCTATCT CTTCTGTTCAA-3' (1214-1232) and 5'-CTCAGTTGCTCCTGGACTA-3'(611-629) are the effective interference sequences of heparanase.Western blot further confirms that before the 10th generation,above interference sequences could effectively inhibit expression of heparanase protein in HepG2 cells.
2.A serial of in vivo and in vitro study indicated that after effectively interfered by the above sequences,the cell growth velocity,single cell clone formation capacity,in vitro invasion capacity and tumorigenesis in nude mice are significantly decreased in HepG2/RNAi/1-1 and HepG2/RNAi/3-3 cells compared with HepG2 and HepG2/RNAi/N cells.
The above results suggest that the heparanase RNAi sequences we screened can effectively inhibit HepG2 liver cancer cells in proliferation,invasion,and tumorigenesis in nude mice.The above heparanase RNAi sequences may therefore represent interesting candidates for the treatment of patients with advanced liver cancer and possibly also with other malignanices.
引文
1.Vlodavsky I,Friedmann Y,Elkin M,Aingom H,Atzmon R.,Ishai-Michaeli R,Bitan M,Pappo O,Peretz T,Michal I,Spector L,Pecker I.Mammalian heparanase:gene cloning,expression and function in tumor progression and metastasis[J].Nat.Med.1999;5(7):793-802
2.Hulett M.D,Freeman C,Hamdorf B.J,Baker R.T,Harris M.J and Parish C.R,Cloning of mammalian heparanase,an important enzyme in tumor invasion and metastasis.Nat.Med.1999;5(14):803-809
3.McKenzie E,Tyson K,Stamps A,Smith P,Turner P,Barry R,Hircock M,Patel S,Barry E,Stubberfield C,Terrett J,Page M,Cloning and expression profiling of Hpa2,a novel mammalian heparanase family member.Biochem Biophys Res Commun.2000;276(3):1170-1177
4.Eccless A.Heparanase:breaking down barriers in tummor[J].Nat Med.1999.5(7):735-736
5.Gohji K,Okamoto M,Kitazawa S,Toyoshima M,Dong J,Katsuoka Y.Heparanase protein and gene expression in bladder cancer[J].J Urology.2001;166(4):1286-1290
6.Friedmann Y,Vlodavsky I,Aingorn H,Aviv A,Peretz T,Pecker I.Expression of heparanase in normal,dysplastic,and neoplastic human colonic mucosa and stroma.Evidence for itsrole in colonic tumorigenesis.Am J Pathol.2000.157(4):1167-1175
7.Tang W,Nakamura Y,Tsujimoto M,Sato M,Wang X,Kurozumi K.Heparanase:a key enzyme in invasion and metastasis of gastric carcinoma.Mod Pathol.2002.15(8):593-598
8.蔡永国,房殿春,杨仕明,罗元辉,杨梦华,王东旭.肝素酶mRNA在胃癌组织中的表达及其与c-met表达的关系.中华医学杂志.2004;84(12):974-978
9.Maxhimer JB,Quiros RM,Stewart R,Dowlatshahi K,Gattuso P,FanM.Heparanase-1expression is associated with the metastatic potential of breast cancer.Surgery.2002;132(9):326-333
10.Ikuta M,Podyma KA,Maruyama K,Enomoto S,Yanagishita M.Expression of heparanase in oral cancer cell lines and oral cancer tissues.Oral 0ncol.2001;37(18):177-184
11.Mikami S,Ohashi K,Usui Y,Nemoto T,Katsube K,Yanagishita M,Nakajima M,Nakamura K,Koike M.Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas[J].Cancer Res.2001,92(10):1062-1073
12.Koliopanos A,Friess H,Kleeff J,Shi X,Liao Q,Pecker I,Vlodavsky I,Zimmermann A,Buchler MW.Heparanase expression in primary and metastatic pancreatic cancer[J].Cancer Res.2001;61(12):4655-4659
13.Marchetti D,Nicolson GL.Human heparanase:a moleculardeterminant of brain metastasis[J].Adv Enzyme Regul.2001;41(41):343-359
14.Xu X,Quiros RM,Maxhimer JB,Jiang P,Marcinek R,Ain KB.Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas:a potential role in tumor metastasis[J].Clin Cancer Res.2003;9(12):5968-5979
15.Ogishima T,Shiina H,Breault JE,Tabatabai L,BassettWW,Enokida H.Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer[J].Clin Cancer Res.2005;11(18):1028-1036
16.Vlodavsky I,Goldshmidt O,Zcharia E,Atzmon R,Rangini-Guatta Z,Elkin M,Peretz T,Friedmann Y.Mammalian heparanase:involvement in cancer metastasis,normal development and angiogenesis[J].Semin Cancer Biol,2002;12(2):121-129
17.杨仕明,汤旭东,陈婷,熊震,陈陵,蔡永国,房殿春.肝素酶:一种新的广谱的肿瘤转移相关抗原在中晚期肿瘤免疫治疗中的作用研究进展[J].世界华人消化杂志;2007;15(8):849-854
18.陈陵,杨仕明,房殿春,王东旭.肝素酶:抗肿瘤转移的新靶点.世界华人消化杂志[J],2004;12(2):439-442
19.Goldshmidt O,Zcharia E,Aingorn H,Guatta-Rangini Z,Atzmon R,Michal I,Pecker I,Mitrani E,Vlodavsky I.Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence[J].J Biol Chem.2001;276(31):29178-29187
20.Cohen E,Atzmon R,Vlodavsky I,Ilan N.Heparanase processing by lysosomal/endosomal protein preparation[J].FEBS Lett.2005,579(11):2334-2338
21.Cai YG,Fang DC,Chen L,Tang XD,Chen T,Yu ST,Luo YH,Xiong Z,Wang DX,Yang SM.Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric cancer tumor cells in vitro.Tumor Biol.2007;28:238-246
22.Sommerfeldt N,Beckhove P,Ge Y,Schutz F,Choi C,Bucur M,Domschke C,Sohn C,Schneeweis A,Rom J,Pollmann D,Leucht D,Vlodavsky I,Schirrmacher V.Heparanase:a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.Cancer Res.2006;66(15):7716-7723
23.汤旭东,万瑛,陈婷,熊震,陈陵,余松涛,罗元辉,杨仕明.小鼠肝素酶H-2K~b限制性CTL表位的预测及其MHC-I亲合力分析.重庆医学.2007;36(9):820-822
24.陈婷,万瑛,汤旭东,房殿春,余松涛,熊震,罗元辉,杨仕明.人肿瘤相关抗原肝素酶HLA-A2.1限制性CTL表位的预测及初步鉴定.第三军医大学学报.2007;29(21):2120-2123
25.Hannon GJ.RNAi Interference[J].Nature.2002;418(6894):244-251
26.Reynolds A,Leake D,Boese Q,Scaringe S,Marshall WS,Khvorova A.Rational siRNA design for RNA interference[J].Nature Biotechnol.2004,22(3):326-330
27.Khvorova A,Reynolds A,Jayasena SD.Functional siRNAs and miRNAs exhibit strand bias[J].Cell.2003,115(4):209-216
28.李永明,赵玉琪等主编.实验分子生物学方法手册.科学出版社,北京,1998年
29.Napoli C,Lemieux C,Jorgensen R.Introduction of a chalcone synthase gene into Petunia results in reversible co-suppression of homologous genes in trans[J].Plant Cell.1990;2(4):279-289
30.Westermarck J,Kahari VM.Regulation of matrix metalloproteinase expression in tumor invasion.Faseb J.1999;13:781-792
31.Eccles SA.Heparanase:breaking down barriers in tumors.Nat Med.1999;5:735-736
32.Finkel E.Potential target found for antimetastasis drugs.Science.1999;285:33-34
33.Hulett MD,Freeman C,Hamdorf BJ,Baker RT,Harris MJ,Parish CR.Cloning of mammalian heparanase,an important enzyme in tumor invasion and metastasis.Nat Med.1999;5:803-809
34.Parish CR,Freeman C,Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.Cancer Res.1999;59:3433-3441
35.Toyoshima M,Nakajima M.Human heparanase:purification,characterization,cloning and expression.J Biol Chem.1999;274:24153-24160
36.Hulett MD,Freeman c,Hamdorf BJ,Barker RT,Harris MJ,Parish CR.Cloning of mammalian heparanase,an important enzeme in tumor innvasion and metastasis.Nat Med.1999;5:803-809
37. Kussie PH,Hulmes JD,Ludwig DL,Patel S,Navarro EC.Seddon AP,Giorgio NA,Bohlen P.Cloning and functional expression of a human heparanase gene.Biochem Biophys Res Commun.1992;261(1):183-187
38. Vlodavsky I,Elkin M,Pappo O,Aingorn H,Atzmon R,Ishai-Michaeli R,Aviv A, Pecker I, Friedmann Y.Mammalian heparanase as mediator of tumor metastasis and angiogenesis.Isr Med Assoc J.2000;2:37-45
39. Pikas DS,Li JP,Vlodavsky I, Lindahl U.Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem.1998;273:18770-18777
40. Marchetti D,Li J.Shen R.Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Res.2000;60: 4767-4770
41. Pillarisetti S,Paka L,Sasaki A,Vanni-Reyes T,Yin B,Parthasarathy N, Wagner WD,Goldberg IJ.Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem.1997,272:15753-15759
42. Goldshmidt O,Zcharia E,Cohen M,Aingorn H,Cohen I,Nadav L,Katz BZ, Geiger B,Vlodavsky I.Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J.2003;17:1015-1025
43. Kuniyasu H,Chihara Y,Kubozoe T,Takahashi T.Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer.Int J Mol Med 2002; 10:333-337
44. Dong J, Kukula AK, Toyoshima M, Nakajima M. Genomic organization and chromosom e localization of the newly identified human heparanase gene. Gene .2000;253:171-178
45. Quiros RM, Kim AW,Maxhimer J,Gattuso P,Xu X,Prinz RA.Differential heparanase-1 expression in malignant and benign pheochromocytomas.J Surg Res. 2002; 108:44-50
46. Ferro V,Dredge K,Liu,LG,Hammond E,Bytheway L,Li CP, Johnstone K,Karoli T,Davis K, Copeman E,Biotech B,Gautam A.PI-88 and novel heparan sulfate mimetics inhibit angiogenesis[J].Seminars in thrombosis and hemostasis.2007,33(5)557-562
47. Tabara H,SarkissianM,Kelly WG, Fleenor J,Grishok A,Timmons L,Fire A, Mello CC.The rde-lgene,RNA interfer-ence,and transposon silencing in C. elegans [J]. Cell. 1999; 99 (2): 123-132
48. Fire A,Xu SQ,MontgomeryMK,Kostas SA,Driver SE,Mello CC.Potent and specific genetic interfer-ence by double-stranded RNA in Caenorhabditis elegans[J]. Nature .1998,391(6669):806-811
49. Timmons L,Fire A.Specific interference by ingested dsRNA[J].Nature.1998;395 (670 5):854
50. Buchon N,Vaury C. RNAi:a defensive RNA-silencing against viruses a transposable elements[J].Heredity.2006;96(2):195-202
51. Herweijer H,Wolff JA.Progress and prospects:naked DNAgene transfer and therapy.Gene Therapy.2003; 10(6):453-458
52. Takabatake Y, Isaka Y,Mizui M,Kawachi H,Takahara S,Imai E.Chemically modified siRNA prolonged RNA interference in renal disease.Biochemical and biophysical research communications.2007;363(2):432-437
53. Billy E, Brondani V,Zhang H ,Muller U,Filipowica W.Specific interference with gene expression dinduced by long ,double stranded RNA inmouse embryonalteratocarcinoma cell lines.Proc Natl Acad SCI.2001 ;98(25): 14428-14433
54. Joe O'Connell.RT-PCR Protocols. Methods in Molecular Biology.2002; 193
55. Yuan B,Lewitter F.siRNA selection program.Whitehead Institution for Biomedical Research, Cambridge.2003
1. Vlodavsky I,Friedmann Y,Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R,Bitan M, Pappo O, Peretz T,Michal I, Spector L,Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis[J].Nat Med.1999;5(7): 793-802
2. Hulett MD,Freeman C,Hamdorf BJ, Baker RT,Harris MJ, Parish CR.Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis[J]. Nat Med. 1999;5(7):803-809
3. Kussie PH,Hulmes JD,Ludwig DL,Patel S,Navarro EC,Seddon AP,Giorgio NA,Bohlen P.Cloning and functional expression of a human heparanase gene[J]. Biochem Biophys Res Commun.1999;261(1): 183-187
4. Toyoshima M,Nakajima M.Human heparanase.Purification, characterization, cloning,and expression[J].J Biol Chem. 1999;274(34):24153-24160
5. Goldshmidt O,Zcharia E, Aingorn H.Guatta-Rangini Z,Atzmon R,Michal I,Pecker I, Mitrani E,Vlodavsky I.Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence[J].J Biol Chem. 2001;276 (31):29178-29187
6. Parish CR,Freeman C,Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity[J]. Cancer Res.1999;59(14):3433-3441
7. Fairbanks MB,Mildner AM,Leone JW,Cavey GS,Mathews WR,Drong RF,Slightom JL, Bienkowski MJ,Smith CW,Bannow CA,Heinrikson RL.Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer[J]. J Biol Chem. 1999;274(42):29587-29590
8. McKenzie E,Young K,Hircock M,Bennett J,Bhaman M,Felix R,Turner P,Stamps A,McMillan D.Saville G,Ng S,Mason S,Snell D,Schofield D,Gong H,Townsend R, Gallagher J,Page M, Parekh R, Stubberfield C. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells[J]. Biochem J. 2003;373(2):423-435
9. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Dan N. Heterodimer formation is essential for heparanase enzymatic activity[J].Biochem Biophys Res Commun. 2003; 308 (4):885-891
10. Mckenzie EA.Heparanase:a target for drug discovery in cancer and inflammation [J].British journal of Pharmacology 2007; 151 (1):1-14
11. Brummelkamp TR, Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science.2002;296(1984):550-553
12. Lee NS,Dohjima T,Bauer G,Li H,Li MJ,Ehsani A,Salvaterra P,Rossi J.Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.Nature Biotechnol. 2002;20(54):500-505
13. Miyagishi M,Taira K.U6 promoter driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells.Nature Biotechnol. 2002;20(54):497-500
14. Paddison PJ,Caudy AA,Bernstein E,Hannon GJ,Conklin DS.Short hairpin RNAs induce sequence-specific silencing in mammalian cells.Genes Dev.2002;16(9):948-958.
15. Paul CP,Good PD,Winer I,Engelke DR.Effective expression of small interfering RNA in human cells.Nature Biotechnol.2002;20(56):505-508
16. Sui G,Soohoo C, Affarel B,Gay F,Shi Y,Forrester WC.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.Proc Natl Acad Sci USA. 2002;99(82):5515-5520
17. Tabara H,Grishok A,Mello CC.RNAi in C. elegans.soaking in the genome sequence. Science. 1998;282(587):430-431
18. Uno F,Fujiwara T,Takata Y,Ohtani S,katsuda K,Takaoka M,Ohkawa T,Naomoto Y, Nakajima M,Tanaka N.Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells[J].Cancer Res.2001;61 (21): 7855-7860
19. Evgeny E,Michael E,Eyal Z,Tamar P, Israel V.Heparanase gene silencing,tumor invasiveness,angiogenesis,and metastasis [J] .National Cancer Insitute. 2004;96 (16): 121 9-1230
20. Zhang ZH,Chen Y,Zhao HJ,Xie CY,Ding J,Hou YT.Silencing of heparanase by siRNA inhibits tumors metastasis and angiogenesis of human breast cancer in vitro and in vivo[J].Cancer biology &therapy.2007;6(4)e 1-e10
21. Yang Y, Macleod V,Dai Y,Khotskaya Y,Shriver Z,Venkataraman G,Sasisekharan R,Naggi A,Torri G,Casu B,Vlodavsky I,Suva LJ.The syndecan-1 heparn sulfate proteoglycan is aviable target for myeloma therapy.Blood.2007; 110(6):2041-2048
22. Ferro V;Dredge K;Liu L;Hammond E;Bytheway I;Li C;Johnstone K;Karoli T;Davis K; Copeman E;Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost.2007;33(5):557-568
23. McKenzie EA.Heparanase:a target for drug discovery in cancer and inflammation.British journal of pharmacology.2007,151(1): 1-14
24. Okawa T,Naomoto Y,Nobuhisa T,Takaoka M,Motoki T,Shirakawa Y,Yamatsuji T,Inoue H,Ouchida M,Gunduz M,Nakajima M,Tanaka N.Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2[J].Clin Cancer Res. 2005;11(22):7995-8005.
25. Ferro V,Hammond E,Fairweather JK.The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation[J].Mini Rev Med Chem.2004;4(6):693-702
26. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies [J]. Cardiovasc Drug Rev. 2004;22(1):1-6
27. Karoli T,Liu L,Fairweather JK,Hammond E,Li CP,Cochran S,Bergefall K,Trybala E, Addison RS,Ferro V. Synthesis, biological activity, and preliminary harmacokinetic evaluation of analogues of a phosphosulfo mannan angiogenesis inhibitor (PI-88). J Med Chem.2005;48(26):8229-8236
28. Cochran S;Li C;Fairweather JK;Kett WC;Coombe DR;Ferro V.Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem.2003;46(21):4601-4608
29. Anon.Heparanase induces VEGF expressionxorrelation with p-38 phosphorylation levels. Clinical&Experimental Metastasis. 2004;21 (7):620-621
30. Ferro V,Dredge K,Liu,LG,Hammond E,Bytheway L,Li CP, Johnstone K,Karoli T,Davis K,Copeman E,Biotech B,Gautam A.PI-88 and novel heparan sulfate mimetics inhibit angiogenesis[J].Seminars in thrombosis and hemostasis.2007 ;33(5)557-562
1. Cox M,Nelson D. Lehninger, Principles of Biochemistry [J] .Freeman .2004,1100
2. Linhardt RJ,Gunay NS.Production and Chemical Processing of Low Molecular Weight Heparins.Semi Thomb Hemo. 1999;25(suppl3):5-16
3. Christopher J, Rutty.Miracle Blood Lubricant: .Connaught and the story of Heparin, 1928-1937[J].Conntact.1996;8(9):4
4. Matthew A,Nugent.Heparin sequencing brings structure to the function of complex oligosaccharides[J]. Commentary.2000; 12(9): 10301 -10303
5. Maria E,Silva,Carl P.Structure of heparin.Biological chemistry.1975;250(17):6841-6846.
6. Casu B.Hepain structure[J].Haemostasisi.1990;20(suppl 1):62-73
7. Lovine MN,Hirsh J,Kehon JG.Heparin-induced bleeding.In:Lane DA,Lindahl V,eds. Heparin:Chemical and Biological Properties,Clinical Applications[M].London VK:Edward Arnold. 1989;517-532
8. Ferro DR,Provasoli A,Ragazzi M,Casu B,Torri G,Bossennec V,Perly B,Sinay P,Petitou M, Choay J.Conformer populations of L-iduronic acid residues in glycosaminoglycan sequence[J].Carbohydr. Res.1990;195(2):157-167.
9. Mulloy B,Forster MJ,Jones C,Davies DB.NMR and molecular-modelling studies of the solution conformation of heparin.Biochem[J].1993,293(3):849-858.
10. Casu B,Lindahl U,Structure and biological interactions of heparin and heparan sulfate[J]. Adv Carbhohyd Chem Biochem.2001,57:159-206
11. Guyton AC,Hall JE.Texbook of Medical Physiology[J]. Elsevier Sauuders.2006,464.
12. Bjork I,Lindahl U.Mechanism of the anticoagulant action of heparin[J].Mol Cell Biochem. 1982;48(3): 161-182
13. Lindahl U,BaEckstroEm G,Thunberg L,Leder IG,Evidence for a3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin[J].Proc Natl Acad Sci MSA.1980;77(11): 6551-6555
14. Lindahl U,Thunberg L,BaEckstroEm G, Riesenfeld J,Nordling K,BjoE rk I,Extension and structural variability of the antithrombinbinding sequence in heparin [J] .J Biol Chem, 1984; 259(20): 2368-2376
15. Bourin M-C,Lindahl U, Glycosaminoglycans and the regulation of blood coagulation [J].B iochem J. 1993;289:313-330
16. Lee AY,Levine MN,Baker RI,Bowden C,Kakkar AK,Prins M,Rickles FR,Julian JA,Haley S,Kovacs MJ,Gent M.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J].N Engl J Med.2003;349(2): 146-153
17. Lee AY,Rickles FR, Julian JA,Gent M,Baker RI,Bowden C, Kakkar AK,Prins M,Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism[J].J Clin Oncol. 2005;23(10):2123-2129
18. Kakkar AK,Levine MN,Kadziola Z,Lemoine NR,Low V,Patel HK,Rustin G,Thomas M, Quigley M,Williamson RC.Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) [J]. J Clin Oncol.2004; 22( 10):1944-1948
19. Altinbas M,Coskun HS,Er O,Ozkan M,Eser B,Unal A,Cetin M,Soyuer S.A randomized clinical trial of combination chemotherapy with and without lowmolecular- weight heparin in small cell lung cancer[J]. J Thromb Haemost.2004;2(8): 1266-1271
20. Klerk CP,Smorenburg SM,Otten HM,Lensing AW,Prins MH,Piovella F,Prandoni P,Bos MM,Richel DJ,van Tienhoven G,Buller HR.The effect of low molecular weight heparin on survival in patients with advanced malignancy[J]. J Clin Oncol.2005;23(10): 2130 -2135.
21. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies[J]. Pharmacol Rev. 2001 ;53(1):93-105
22. Leo R,Zacharski,MD,James T,Loynes,MD.The heparins and cancer. Thromb Haemost. 1998; 80(1): 10-23.
23. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost [J].1998;80(1): 10-23.
24. Niers TM,Klerk CP,DiNisio M,Van Noorden CJ,Buller HR,Reitsma PH,Richel DJ. Mechanisms of heparin induced cancer activity in experimental cancer models[J].Crit Rev Oncol Hematol.2007;61(3): 195-207
25. Lee AE,Rogers LA,Longcroft JM, Jeffery RE.Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid[J].Clin Exp Metastasis. 1990;8(2): 165-171
26. Vlodavsky I,Mohsen M,Lider O,Svahn CM,Ekre HP,Vigoda M, Ishai Michaeli R, Peretz T. Inhibition of tumor metastasis by heparanase inhibiting species of heparin[J].Invasion Metastasis. 1994;14(1-6):290-302
27. Poggi A,Rossi C,Casella N,Bruno C,Sturiale L,Dossi C,Naggi A. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosansulfates from E.coli K5 polysaccharide[J]. Semin Thromb Hemost. 2002;28(4):383-392
28. Amirkhosravi A,Mousa SA, Amaya M.Francis JL.Antimetastatic effect of tinzaparin, a low-molecular-weightheparin[J]. J Thromb Haemost. 2003;1(9): 1972-1976
29. Ludwig RJ,Boehme B,Podda M,Henschler R, Jager E, Tandi C,Boehncke WH,Zollner TM, Kaufmann R,Gille J.Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis[J]. Cancer Res. 2004;64(8):2743-2750
30. Borsig L,Wong R,Feramisco J,Nadeau DR,Varki NM,Varki A.Heparin and cancer revisited:mechanistic connections involving platelets,P-selectin, carcinoma mucins,and tumor metastasis[J]. Proc Natl Acad Sci USA.2001;98(6):3352-3357
31. Borsig L,Wong R,Hynes RO,Varki NM,Varki A.Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis[J]. Proc Natl Acad Sci USA .2002;99(4):2193-2198
32. Sorensen HT,Mellemkjaer L, Olsen JH,Baron JA.Prognosis of cancers associated with venous thromboembolism. N Engl J Med.2000;343:1846-1850
33. Rickles FR,Patierno S,Fernandez PM.Tissue factor,thrombin,and cancer. Chest. 2003; 124:58S-68S
34. Nasser NJ,Sarig G,Brenner B,Nevo E, Goldshmidt O,Zcharia E,Li JP,Vlodavsky I. Heparanase neutralizes the anticoagulation propertiesof heparin and low molecular weight heparin.J Thromb Haemost. 2006;4:560-565
35. Zacharski LR,Ornstein DL,Mamourian AC. Low-molecular-weight heparin and cancer[J]. Semin Thromb Hemost. 2000;26(suppl 1):69-77
36. Lever R,Page CP.Novel drug development opportunities for heparin.Nat Rev Drug Discov.2002,1(2):140-148
37. Stevenson JL,Choi SH, Varki A.Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity[J].Clin Cancer Res.2005;11(19):7003-7011
38. Nelson RM,Cecconi O,Roberts WG,Aruffo A,Linhardt RJ,Bevilacqua MP.Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation[J].Blood. 1993; 82(11):3253-3258
39. Koenig A,Norgard Sumnicht K,Linhardt R,Varki A.Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents[J].J ClinInvest. 1998;101(4):877-889
40. Wang L,Brown JR,Varki A,Esko JD.Heparin's inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins[J]. J Clin Invest.2002; 110(1): 127-136
41. Wei M,Gao Y,Tian M,Li N,Hao S,Zeng X.Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells[J]. Cancer Lett. 2005, 229(1):123 -126.
42. Parish CR, Freeman C,Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity[J].Cancer Res.1999;59 (14):3433-3441
43. Nasser NJ,Sarig G,Brenner B,Nevo E,Goldshmidt O,Zcharia E,Li JP,Vlodavsky I.Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin[J].J Thromb Haemost. 2006;4(3):560-565
44. Thodiyil P, Kakkar AK.Can low-molecularweight heparins improve outcome in patients with cancer?[J]. Cancer Treat Rev. 2002;28(3): 151-155
45. Bar-Ner M,Eldor A,Wasserman L,Matzner Y,Cohen IR,Fuks Z,Vlodavsky I.Inhibition of heparanase-mediated degradation of extracellularmatrix heparan sulfate by non-anticoagulant heparinspecies[J]. Blood.1987;70(6):551-557
46. Parish CR,Coombe DR,Jakobsen KB,Bennett FA,Underwood PA.Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases[J]. Int J Cancer. 1987;40(4):511-518
47. Nakajima M,Irimura T,Nicolson GL.Heparanases and tumor metastasis[J].J Cell Biochem. 1988;36(2):157-167
48. Vlodavsky I,Mohsen M,Lider O,Svahn CM,Ekre HP,Vigoda M,Ishai-Michaeli R,Peretz T. Inhibition of tumor metastasis by heparanase inhibiting species of Heparin [J]. Invasion Metastasis. 1994; 14(1-6):290-302
49. Edovitsky E,Elkin M,Zcharia E,Peretz T,Vlodavsky I.Heparanase gene silencing, tumor invasiveness, angiogenesis,and metastasis [J]. J Natl Cancer Inst. 2004;96(16): 1219-1230
50. Borsig L.Antimetastatic activities of modified heparins: Selectin inhibition by heparin attenuates [J]. Seminars in thrombosis and hemostasis.2007 33(5):540-546
51. Dirk Simonis,Katrin Christ,Susanne Alban,Gerd Bendas.Affinity and Kinetics of Different Heparins Binding to P- and L-Selectin[J]. Semin Thromb Hemost. 2007; 33 (5):534-539
52. Fan SQ,Qin LY,Cai JL,Zhu GY,Bin X,Yan HS.Effect of heparin on production of basic fibroblast growth factor and transforming growth factor-betal by human normal skin and hyperplastic scar fibroblasts. Burn Care&Research.2007;28(5):734-741
53. Yu YQ,Gu ST, Huang H,Wen TQ.Combination of BFGF,heparin and laminin induce the generation of dopaminergic neurons from rat neural stem cells both in vitro and in vivo. Neurological Sciences.2007 ;255(1-2)81 -86
54. Lee JS,Go DH, Bae JW,Lee SJ,Park KD.Heparin conjugated polymeric micelle for long-terin delivery of basic fibroblat growth factor.Controlled Release.2007;117(2): 204-209
55. Pike DB,Cai SS,Pomraning KR,Firpo MA,Fisher RJ,Shu XZ,Prestwich GD,Peattie RA. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and BFGF. Biomaterials. 2006; 27 (30):5242-5251
56. Krilleke D,DeErkenez Z ,Schubert W,Giri I,Robinson GS,Ng YS,Shima DT. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. BIOLOGICAL CHEMISTRY .2007;282 (38): 28045-28056
57. Springer ML ,Banfi A,Ye JQ,Degenfeld G,Kraft PE,Saini SA,Kpasi NK,Blau HM. Localization of vascular response to VEGF is not dependent on heparin binding. Faseb Journal.2007; 21 (9): 2074-2085
58. Begum S,Zhang Y,Shintani T,Toratani S,Sat JD,Okamoto T. Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis. Oncology Reports .2007,17 (3): 591-596
59. Pufe T,Groth G,Goldring MB,Tillmann B,Mentlein R. Effects of pleiotrophin, a heparin-binding growth factor,on human primary and immortalized chondrocytes. Osteoarthritis and Cartilage.2007; 15(2): 155-162
60. Cohen I,Pappo O,Elkin M,San T,Bar Shavit R,Hazan R,Peretz T,Vlodavsky I, Abramovitch R.Heparanase promotes growth,angiogenesis and survival of primary breast tumors [J].Int J Cancer .2006;118(7):1609-1617
61. Vlodavsky I,Abboud Jarrous G,Elkin M,Naggi A,Casu B,Sasisekharan R, Ilan N.The impact of heparanase and heparin on cancer metastasis and angiogenesis [J].Pathophysiol Haemost Thromb .2006;35(1-2):116-127
62. Ferro V,Dredge K,Liu,LG,Hammond E,Bytheway L,Li CP,Johnstone K,Karoli T,Davis K,Copeman E,Biotech B,Gautam A.PI-88 and novel heparan sulfate mimetics inhibit angiogenesis[J].Seminars in thrombosis and hemostasis.2007;33(5):557-562
63. Karpatkin S,Pearlstein E,Ambrogio C,Coller BS.Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81 (4): 1012-1019
64. Nieswandt B,Hafner M,Echtenacher B,Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets [J]. Cancer Res . 1999;59(6): 1295-1300
65. Sciumbata T,Caretto P,Pirovano P,Pozzi P,Cremonesi P,Galimberti G,Leoni F,Marcucci F. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival [J]. Invasion Metastasis. 1996;16(3):132-143
66. Laubli H,Stevenson JL,Varki A,Varki NM,Borsig L.L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest [J]. Cancer Res.2006;66(3): 1536-1542
67. Parish CR,Freeman C.Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro asssays for angiogenesis and heparanase activity [J].Cancer Res.1999;59(14):3433-41
68. Chen PJ,Lee PH,Lin DY.Novel heapranase inhibitor PI-88 extends disease free survival in a randomized phase II adjuvant clinical trial in patients with hepatocellular carcinoma(HCC) after curative resection [J]. J Hepatology.2007 ;46( Suppl 1): S293
69. Smorenburg SM,Van Noorden CJ.The complex efects of heparins on cancer progression and metastasis in experimental studies[J] .Pharmacol Rev.2001;53(1):93-105
70. Tyrrell DJ,Horne AP,Holme KR,Preuss JM,Page CP.Heparin in inflammation:Potential therapeutic applications beyond anticoagulation[J].Adv Pharmacol.1999;46: 151-208
71. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibrolast growth factor [J].Cancer Metastasis Rev.1996;15(2):177-186
72. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini Guatta Z, Elkin M, Peretz T, Friedmann Y. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development[J].Semin Cancer Biol,2002; 12(2): 121-129
73. Pross M, Lippert H, Misselwitz F, Nestler G, Kruger S, Langer H, Halangk W, Schulz HU. Low-Molecular weight Heparin (reviparin) dimishes tunlor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy[J]. Thromb Res.2003;110(4):210-215
2.Hulett M.D,Freeman C,Hamdorf B.J,Baker R.T,Harris M.J and Parish C.R,Cloning of mammalian heparanase,an important enzyme in tumor invasion and metastasis.Nat.Med.1999;5(14):803-809
3.McKenzie E,Tyson K,Stamps A,Smith P,Turner P,Barry R,Hircock M,Patel S,Barry E,Stubberfield C,Terrett J,Page M,Cloning and expression profiling of Hpa2,a novel mammalian heparanase family member.Biochem Biophys Res Commun.2000;276(3):1170-1177
4.Eccless A.Heparanase:breaking down barriers in tummor[J].Nat Med.1999.5(7):735-736
5.Gohji K,Okamoto M,Kitazawa S,Toyoshima M,Dong J,Katsuoka Y.Heparanase protein and gene expression in bladder cancer[J].J Urology.2001;166(4):1286-1290
6.Friedmann Y,Vlodavsky I,Aingorn H,Aviv A,Peretz T,Pecker I.Expression of heparanase in normal,dysplastic,and neoplastic human colonic mucosa and stroma.Evidence for itsrole in colonic tumorigenesis.Am J Pathol.2000.157(4):1167-1175
7.Tang W,Nakamura Y,Tsujimoto M,Sato M,Wang X,Kurozumi K.Heparanase:a key enzyme in invasion and metastasis of gastric carcinoma.Mod Pathol.2002.15(8):593-598
8.蔡永国,房殿春,杨仕明,罗元辉,杨梦华,王东旭.肝素酶mRNA在胃癌组织中的表达及其与c-met表达的关系.中华医学杂志.2004;84(12):974-978
9.Maxhimer JB,Quiros RM,Stewart R,Dowlatshahi K,Gattuso P,FanM.Heparanase-1expression is associated with the metastatic potential of breast cancer.Surgery.2002;132(9):326-333
10.Ikuta M,Podyma KA,Maruyama K,Enomoto S,Yanagishita M.Expression of heparanase in oral cancer cell lines and oral cancer tissues.Oral 0ncol.2001;37(18):177-184
11.Mikami S,Ohashi K,Usui Y,Nemoto T,Katsube K,Yanagishita M,Nakajima M,Nakamura K,Koike M.Loss of syndecan-1 and increased expression of heparanase in invasive esophageal carcinomas[J].Cancer Res.2001,92(10):1062-1073
12.Koliopanos A,Friess H,Kleeff J,Shi X,Liao Q,Pecker I,Vlodavsky I,Zimmermann A,Buchler MW.Heparanase expression in primary and metastatic pancreatic cancer[J].Cancer Res.2001;61(12):4655-4659
13.Marchetti D,Nicolson GL.Human heparanase:a moleculardeterminant of brain metastasis[J].Adv Enzyme Regul.2001;41(41):343-359
14.Xu X,Quiros RM,Maxhimer JB,Jiang P,Marcinek R,Ain KB.Inverse correlation between heparan sulfate composition and heparanase-1 gene expression in thyroid papillary carcinomas:a potential role in tumor metastasis[J].Clin Cancer Res.2003;9(12):5968-5979
15.Ogishima T,Shiina H,Breault JE,Tabatabai L,BassettWW,Enokida H.Increased heparanase expression is caused by promoter hypomethylation and up-regulation of transcriptional factor early growth response-1 in human prostate cancer[J].Clin Cancer Res.2005;11(18):1028-1036
16.Vlodavsky I,Goldshmidt O,Zcharia E,Atzmon R,Rangini-Guatta Z,Elkin M,Peretz T,Friedmann Y.Mammalian heparanase:involvement in cancer metastasis,normal development and angiogenesis[J].Semin Cancer Biol,2002;12(2):121-129
17.杨仕明,汤旭东,陈婷,熊震,陈陵,蔡永国,房殿春.肝素酶:一种新的广谱的肿瘤转移相关抗原在中晚期肿瘤免疫治疗中的作用研究进展[J].世界华人消化杂志;2007;15(8):849-854
18.陈陵,杨仕明,房殿春,王东旭.肝素酶:抗肿瘤转移的新靶点.世界华人消化杂志[J],2004;12(2):439-442
19.Goldshmidt O,Zcharia E,Aingorn H,Guatta-Rangini Z,Atzmon R,Michal I,Pecker I,Mitrani E,Vlodavsky I.Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence[J].J Biol Chem.2001;276(31):29178-29187
20.Cohen E,Atzmon R,Vlodavsky I,Ilan N.Heparanase processing by lysosomal/endosomal protein preparation[J].FEBS Lett.2005,579(11):2334-2338
21.Cai YG,Fang DC,Chen L,Tang XD,Chen T,Yu ST,Luo YH,Xiong Z,Wang DX,Yang SM.Dendritic cells reconstituted with a human heparanase gene induce potent cytotoxic T-cell responses against gastric cancer tumor cells in vitro.Tumor Biol.2007;28:238-246
22.Sommerfeldt N,Beckhove P,Ge Y,Schutz F,Choi C,Bucur M,Domschke C,Sohn C,Schneeweis A,Rom J,Pollmann D,Leucht D,Vlodavsky I,Schirrmacher V.Heparanase:a new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes.Cancer Res.2006;66(15):7716-7723
23.汤旭东,万瑛,陈婷,熊震,陈陵,余松涛,罗元辉,杨仕明.小鼠肝素酶H-2K~b限制性CTL表位的预测及其MHC-I亲合力分析.重庆医学.2007;36(9):820-822
24.陈婷,万瑛,汤旭东,房殿春,余松涛,熊震,罗元辉,杨仕明.人肿瘤相关抗原肝素酶HLA-A2.1限制性CTL表位的预测及初步鉴定.第三军医大学学报.2007;29(21):2120-2123
25.Hannon GJ.RNAi Interference[J].Nature.2002;418(6894):244-251
26.Reynolds A,Leake D,Boese Q,Scaringe S,Marshall WS,Khvorova A.Rational siRNA design for RNA interference[J].Nature Biotechnol.2004,22(3):326-330
27.Khvorova A,Reynolds A,Jayasena SD.Functional siRNAs and miRNAs exhibit strand bias[J].Cell.2003,115(4):209-216
28.李永明,赵玉琪等主编.实验分子生物学方法手册.科学出版社,北京,1998年
29.Napoli C,Lemieux C,Jorgensen R.Introduction of a chalcone synthase gene into Petunia results in reversible co-suppression of homologous genes in trans[J].Plant Cell.1990;2(4):279-289
30.Westermarck J,Kahari VM.Regulation of matrix metalloproteinase expression in tumor invasion.Faseb J.1999;13:781-792
31.Eccles SA.Heparanase:breaking down barriers in tumors.Nat Med.1999;5:735-736
32.Finkel E.Potential target found for antimetastasis drugs.Science.1999;285:33-34
33.Hulett MD,Freeman C,Hamdorf BJ,Baker RT,Harris MJ,Parish CR.Cloning of mammalian heparanase,an important enzyme in tumor invasion and metastasis.Nat Med.1999;5:803-809
34.Parish CR,Freeman C,Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity.Cancer Res.1999;59:3433-3441
35.Toyoshima M,Nakajima M.Human heparanase:purification,characterization,cloning and expression.J Biol Chem.1999;274:24153-24160
36.Hulett MD,Freeman c,Hamdorf BJ,Barker RT,Harris MJ,Parish CR.Cloning of mammalian heparanase,an important enzeme in tumor innvasion and metastasis.Nat Med.1999;5:803-809
37. Kussie PH,Hulmes JD,Ludwig DL,Patel S,Navarro EC.Seddon AP,Giorgio NA,Bohlen P.Cloning and functional expression of a human heparanase gene.Biochem Biophys Res Commun.1992;261(1):183-187
38. Vlodavsky I,Elkin M,Pappo O,Aingorn H,Atzmon R,Ishai-Michaeli R,Aviv A, Pecker I, Friedmann Y.Mammalian heparanase as mediator of tumor metastasis and angiogenesis.Isr Med Assoc J.2000;2:37-45
39. Pikas DS,Li JP,Vlodavsky I, Lindahl U.Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem.1998;273:18770-18777
40. Marchetti D,Li J.Shen R.Astrocytes contribute to the brain-metastatic specificity of melanoma cells by producing heparanase. Cancer Res.2000;60: 4767-4770
41. Pillarisetti S,Paka L,Sasaki A,Vanni-Reyes T,Yin B,Parthasarathy N, Wagner WD,Goldberg IJ.Endothelial cell heparanase modulation of lipoprotein lipase activity. Evidence that heparan sulfate oligosaccharide is an extracellular chaperone. J Biol Chem.1997,272:15753-15759
42. Goldshmidt O,Zcharia E,Cohen M,Aingorn H,Cohen I,Nadav L,Katz BZ, Geiger B,Vlodavsky I.Heparanase mediates cell adhesion independent of its enzymatic activity. FASEB J.2003;17:1015-1025
43. Kuniyasu H,Chihara Y,Kubozoe T,Takahashi T.Co-expression of CD44v3 and heparanase is correlated with metastasis of human colon cancer.Int J Mol Med 2002; 10:333-337
44. Dong J, Kukula AK, Toyoshima M, Nakajima M. Genomic organization and chromosom e localization of the newly identified human heparanase gene. Gene .2000;253:171-178
45. Quiros RM, Kim AW,Maxhimer J,Gattuso P,Xu X,Prinz RA.Differential heparanase-1 expression in malignant and benign pheochromocytomas.J Surg Res. 2002; 108:44-50
46. Ferro V,Dredge K,Liu,LG,Hammond E,Bytheway L,Li CP, Johnstone K,Karoli T,Davis K, Copeman E,Biotech B,Gautam A.PI-88 and novel heparan sulfate mimetics inhibit angiogenesis[J].Seminars in thrombosis and hemostasis.2007,33(5)557-562
47. Tabara H,SarkissianM,Kelly WG, Fleenor J,Grishok A,Timmons L,Fire A, Mello CC.The rde-lgene,RNA interfer-ence,and transposon silencing in C. elegans [J]. Cell. 1999; 99 (2): 123-132
48. Fire A,Xu SQ,MontgomeryMK,Kostas SA,Driver SE,Mello CC.Potent and specific genetic interfer-ence by double-stranded RNA in Caenorhabditis elegans[J]. Nature .1998,391(6669):806-811
49. Timmons L,Fire A.Specific interference by ingested dsRNA[J].Nature.1998;395 (670 5):854
50. Buchon N,Vaury C. RNAi:a defensive RNA-silencing against viruses a transposable elements[J].Heredity.2006;96(2):195-202
51. Herweijer H,Wolff JA.Progress and prospects:naked DNAgene transfer and therapy.Gene Therapy.2003; 10(6):453-458
52. Takabatake Y, Isaka Y,Mizui M,Kawachi H,Takahara S,Imai E.Chemically modified siRNA prolonged RNA interference in renal disease.Biochemical and biophysical research communications.2007;363(2):432-437
53. Billy E, Brondani V,Zhang H ,Muller U,Filipowica W.Specific interference with gene expression dinduced by long ,double stranded RNA inmouse embryonalteratocarcinoma cell lines.Proc Natl Acad SCI.2001 ;98(25): 14428-14433
54. Joe O'Connell.RT-PCR Protocols. Methods in Molecular Biology.2002; 193
55. Yuan B,Lewitter F.siRNA selection program.Whitehead Institution for Biomedical Research, Cambridge.2003
1. Vlodavsky I,Friedmann Y,Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R,Bitan M, Pappo O, Peretz T,Michal I, Spector L,Pecker I. Mammalian heparanase: gene cloning, expression and function in tumor progression and metastasis[J].Nat Med.1999;5(7): 793-802
2. Hulett MD,Freeman C,Hamdorf BJ, Baker RT,Harris MJ, Parish CR.Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis[J]. Nat Med. 1999;5(7):803-809
3. Kussie PH,Hulmes JD,Ludwig DL,Patel S,Navarro EC,Seddon AP,Giorgio NA,Bohlen P.Cloning and functional expression of a human heparanase gene[J]. Biochem Biophys Res Commun.1999;261(1): 183-187
4. Toyoshima M,Nakajima M.Human heparanase.Purification, characterization, cloning,and expression[J].J Biol Chem. 1999;274(34):24153-24160
5. Goldshmidt O,Zcharia E, Aingorn H.Guatta-Rangini Z,Atzmon R,Michal I,Pecker I, Mitrani E,Vlodavsky I.Expression pattern and secretion of human and chicken heparanase are determined by their signal peptide sequence[J].J Biol Chem. 2001;276 (31):29178-29187
6. Parish CR,Freeman C,Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity[J]. Cancer Res.1999;59(14):3433-3441
7. Fairbanks MB,Mildner AM,Leone JW,Cavey GS,Mathews WR,Drong RF,Slightom JL, Bienkowski MJ,Smith CW,Bannow CA,Heinrikson RL.Processing of the human heparanase precursor and evidence that the active enzyme is a heterodimer[J]. J Biol Chem. 1999;274(42):29587-29590
8. McKenzie E,Young K,Hircock M,Bennett J,Bhaman M,Felix R,Turner P,Stamps A,McMillan D.Saville G,Ng S,Mason S,Snell D,Schofield D,Gong H,Townsend R, Gallagher J,Page M, Parekh R, Stubberfield C. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells[J]. Biochem J. 2003;373(2):423-435
9. Levy-Adam F, Miao HQ, Heinrikson RL, Vlodavsky I, Dan N. Heterodimer formation is essential for heparanase enzymatic activity[J].Biochem Biophys Res Commun. 2003; 308 (4):885-891
10. Mckenzie EA.Heparanase:a target for drug discovery in cancer and inflammation [J].British journal of Pharmacology 2007; 151 (1):1-14
11. Brummelkamp TR, Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science.2002;296(1984):550-553
12. Lee NS,Dohjima T,Bauer G,Li H,Li MJ,Ehsani A,Salvaterra P,Rossi J.Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells.Nature Biotechnol. 2002;20(54):500-505
13. Miyagishi M,Taira K.U6 promoter driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells.Nature Biotechnol. 2002;20(54):497-500
14. Paddison PJ,Caudy AA,Bernstein E,Hannon GJ,Conklin DS.Short hairpin RNAs induce sequence-specific silencing in mammalian cells.Genes Dev.2002;16(9):948-958.
15. Paul CP,Good PD,Winer I,Engelke DR.Effective expression of small interfering RNA in human cells.Nature Biotechnol.2002;20(56):505-508
16. Sui G,Soohoo C, Affarel B,Gay F,Shi Y,Forrester WC.A DNA vector-based RNAi technology to suppress gene expression in mammalian cells.Proc Natl Acad Sci USA. 2002;99(82):5515-5520
17. Tabara H,Grishok A,Mello CC.RNAi in C. elegans.soaking in the genome sequence. Science. 1998;282(587):430-431
18. Uno F,Fujiwara T,Takata Y,Ohtani S,katsuda K,Takaoka M,Ohkawa T,Naomoto Y, Nakajima M,Tanaka N.Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells[J].Cancer Res.2001;61 (21): 7855-7860
19. Evgeny E,Michael E,Eyal Z,Tamar P, Israel V.Heparanase gene silencing,tumor invasiveness,angiogenesis,and metastasis [J] .National Cancer Insitute. 2004;96 (16): 121 9-1230
20. Zhang ZH,Chen Y,Zhao HJ,Xie CY,Ding J,Hou YT.Silencing of heparanase by siRNA inhibits tumors metastasis and angiogenesis of human breast cancer in vitro and in vivo[J].Cancer biology &therapy.2007;6(4)e 1-e10
21. Yang Y, Macleod V,Dai Y,Khotskaya Y,Shriver Z,Venkataraman G,Sasisekharan R,Naggi A,Torri G,Casu B,Vlodavsky I,Suva LJ.The syndecan-1 heparn sulfate proteoglycan is aviable target for myeloma therapy.Blood.2007; 110(6):2041-2048
22. Ferro V;Dredge K;Liu L;Hammond E;Bytheway I;Li C;Johnstone K;Karoli T;Davis K; Copeman E;Gautam A. PI-88 and novel heparan sulfate mimetics inhibit angiogenesis. Semin Thromb Hemost.2007;33(5):557-568
23. McKenzie EA.Heparanase:a target for drug discovery in cancer and inflammation.British journal of pharmacology.2007,151(1): 1-14
24. Okawa T,Naomoto Y,Nobuhisa T,Takaoka M,Motoki T,Shirakawa Y,Yamatsuji T,Inoue H,Ouchida M,Gunduz M,Nakajima M,Tanaka N.Heparanase is involved in angiogenesis in esophageal cancer through induction of cyclooxygenase-2[J].Clin Cancer Res. 2005;11(22):7995-8005.
25. Ferro V,Hammond E,Fairweather JK.The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation[J].Mini Rev Med Chem.2004;4(6):693-702
26. Khachigian LM, Parish CR. Phosphomannopentaose sulfate (PI-88): heparan sulfate mimetic with clinical potential in multiple vascular pathologies [J]. Cardiovasc Drug Rev. 2004;22(1):1-6
27. Karoli T,Liu L,Fairweather JK,Hammond E,Li CP,Cochran S,Bergefall K,Trybala E, Addison RS,Ferro V. Synthesis, biological activity, and preliminary harmacokinetic evaluation of analogues of a phosphosulfo mannan angiogenesis inhibitor (PI-88). J Med Chem.2005;48(26):8229-8236
28. Cochran S;Li C;Fairweather JK;Kett WC;Coombe DR;Ferro V.Probing the interactions of phosphosulfomannans with angiogenic growth factors by surface plasmon resonance. J Med Chem.2003;46(21):4601-4608
29. Anon.Heparanase induces VEGF expressionxorrelation with p-38 phosphorylation levels. Clinical&Experimental Metastasis. 2004;21 (7):620-621
30. Ferro V,Dredge K,Liu,LG,Hammond E,Bytheway L,Li CP, Johnstone K,Karoli T,Davis K,Copeman E,Biotech B,Gautam A.PI-88 and novel heparan sulfate mimetics inhibit angiogenesis[J].Seminars in thrombosis and hemostasis.2007 ;33(5)557-562
1. Cox M,Nelson D. Lehninger, Principles of Biochemistry [J] .Freeman .2004,1100
2. Linhardt RJ,Gunay NS.Production and Chemical Processing of Low Molecular Weight Heparins.Semi Thomb Hemo. 1999;25(suppl3):5-16
3. Christopher J, Rutty.Miracle Blood Lubricant: .Connaught and the story of Heparin, 1928-1937[J].Conntact.1996;8(9):4
4. Matthew A,Nugent.Heparin sequencing brings structure to the function of complex oligosaccharides[J]. Commentary.2000; 12(9): 10301 -10303
5. Maria E,Silva,Carl P.Structure of heparin.Biological chemistry.1975;250(17):6841-6846.
6. Casu B.Hepain structure[J].Haemostasisi.1990;20(suppl 1):62-73
7. Lovine MN,Hirsh J,Kehon JG.Heparin-induced bleeding.In:Lane DA,Lindahl V,eds. Heparin:Chemical and Biological Properties,Clinical Applications[M].London VK:Edward Arnold. 1989;517-532
8. Ferro DR,Provasoli A,Ragazzi M,Casu B,Torri G,Bossennec V,Perly B,Sinay P,Petitou M, Choay J.Conformer populations of L-iduronic acid residues in glycosaminoglycan sequence[J].Carbohydr. Res.1990;195(2):157-167.
9. Mulloy B,Forster MJ,Jones C,Davies DB.NMR and molecular-modelling studies of the solution conformation of heparin.Biochem[J].1993,293(3):849-858.
10. Casu B,Lindahl U,Structure and biological interactions of heparin and heparan sulfate[J]. Adv Carbhohyd Chem Biochem.2001,57:159-206
11. Guyton AC,Hall JE.Texbook of Medical Physiology[J]. Elsevier Sauuders.2006,464.
12. Bjork I,Lindahl U.Mechanism of the anticoagulant action of heparin[J].Mol Cell Biochem. 1982;48(3): 161-182
13. Lindahl U,BaEckstroEm G,Thunberg L,Leder IG,Evidence for a3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin[J].Proc Natl Acad Sci MSA.1980;77(11): 6551-6555
14. Lindahl U,Thunberg L,BaEckstroEm G, Riesenfeld J,Nordling K,BjoE rk I,Extension and structural variability of the antithrombinbinding sequence in heparin [J] .J Biol Chem, 1984; 259(20): 2368-2376
15. Bourin M-C,Lindahl U, Glycosaminoglycans and the regulation of blood coagulation [J].B iochem J. 1993;289:313-330
16. Lee AY,Levine MN,Baker RI,Bowden C,Kakkar AK,Prins M,Rickles FR,Julian JA,Haley S,Kovacs MJ,Gent M.Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer[J].N Engl J Med.2003;349(2): 146-153
17. Lee AY,Rickles FR, Julian JA,Gent M,Baker RI,Bowden C, Kakkar AK,Prins M,Levine MN. Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism[J].J Clin Oncol. 2005;23(10):2123-2129
18. Kakkar AK,Levine MN,Kadziola Z,Lemoine NR,Low V,Patel HK,Rustin G,Thomas M, Quigley M,Williamson RC.Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS) [J]. J Clin Oncol.2004; 22( 10):1944-1948
19. Altinbas M,Coskun HS,Er O,Ozkan M,Eser B,Unal A,Cetin M,Soyuer S.A randomized clinical trial of combination chemotherapy with and without lowmolecular- weight heparin in small cell lung cancer[J]. J Thromb Haemost.2004;2(8): 1266-1271
20. Klerk CP,Smorenburg SM,Otten HM,Lensing AW,Prins MH,Piovella F,Prandoni P,Bos MM,Richel DJ,van Tienhoven G,Buller HR.The effect of low molecular weight heparin on survival in patients with advanced malignancy[J]. J Clin Oncol.2005;23(10): 2130 -2135.
21. Smorenburg SM, Van Noorden CJ. The complex effects of heparins on cancer progression and metastasis in experimental studies[J]. Pharmacol Rev. 2001 ;53(1):93-105
22. Leo R,Zacharski,MD,James T,Loynes,MD.The heparins and cancer. Thromb Haemost. 1998; 80(1): 10-23.
23. Zacharski LR, Ornstein DL. Heparin and cancer. Thromb Haemost [J].1998;80(1): 10-23.
24. Niers TM,Klerk CP,DiNisio M,Van Noorden CJ,Buller HR,Reitsma PH,Richel DJ. Mechanisms of heparin induced cancer activity in experimental cancer models[J].Crit Rev Oncol Hematol.2007;61(3): 195-207
25. Lee AE,Rogers LA,Longcroft JM, Jeffery RE.Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid[J].Clin Exp Metastasis. 1990;8(2): 165-171
26. Vlodavsky I,Mohsen M,Lider O,Svahn CM,Ekre HP,Vigoda M, Ishai Michaeli R, Peretz T. Inhibition of tumor metastasis by heparanase inhibiting species of heparin[J].Invasion Metastasis. 1994;14(1-6):290-302
27. Poggi A,Rossi C,Casella N,Bruno C,Sturiale L,Dossi C,Naggi A. Inhibition of B16-BL6 melanoma lung colonies by semisynthetic sulfaminoheparosansulfates from E.coli K5 polysaccharide[J]. Semin Thromb Hemost. 2002;28(4):383-392
28. Amirkhosravi A,Mousa SA, Amaya M.Francis JL.Antimetastatic effect of tinzaparin, a low-molecular-weightheparin[J]. J Thromb Haemost. 2003;1(9): 1972-1976
29. Ludwig RJ,Boehme B,Podda M,Henschler R, Jager E, Tandi C,Boehncke WH,Zollner TM, Kaufmann R,Gille J.Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis[J]. Cancer Res. 2004;64(8):2743-2750
30. Borsig L,Wong R,Feramisco J,Nadeau DR,Varki NM,Varki A.Heparin and cancer revisited:mechanistic connections involving platelets,P-selectin, carcinoma mucins,and tumor metastasis[J]. Proc Natl Acad Sci USA.2001;98(6):3352-3357
31. Borsig L,Wong R,Hynes RO,Varki NM,Varki A.Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis[J]. Proc Natl Acad Sci USA .2002;99(4):2193-2198
32. Sorensen HT,Mellemkjaer L, Olsen JH,Baron JA.Prognosis of cancers associated with venous thromboembolism. N Engl J Med.2000;343:1846-1850
33. Rickles FR,Patierno S,Fernandez PM.Tissue factor,thrombin,and cancer. Chest. 2003; 124:58S-68S
34. Nasser NJ,Sarig G,Brenner B,Nevo E, Goldshmidt O,Zcharia E,Li JP,Vlodavsky I. Heparanase neutralizes the anticoagulation propertiesof heparin and low molecular weight heparin.J Thromb Haemost. 2006;4:560-565
35. Zacharski LR,Ornstein DL,Mamourian AC. Low-molecular-weight heparin and cancer[J]. Semin Thromb Hemost. 2000;26(suppl 1):69-77
36. Lever R,Page CP.Novel drug development opportunities for heparin.Nat Rev Drug Discov.2002,1(2):140-148
37. Stevenson JL,Choi SH, Varki A.Differential metastasis inhibition by clinically relevant levels of heparins-correlation with selectin inhibition, not antithrombotic activity[J].Clin Cancer Res.2005;11(19):7003-7011
38. Nelson RM,Cecconi O,Roberts WG,Aruffo A,Linhardt RJ,Bevilacqua MP.Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation[J].Blood. 1993; 82(11):3253-3258
39. Koenig A,Norgard Sumnicht K,Linhardt R,Varki A.Differential interactions of heparin and heparan sulfate glycosaminoglycans with the selectins. Implications for the use of unfractionated and low molecular weight heparins as therapeutic agents[J].J ClinInvest. 1998;101(4):877-889
40. Wang L,Brown JR,Varki A,Esko JD.Heparin's inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L- and P-selectins[J]. J Clin Invest.2002; 110(1): 127-136
41. Wei M,Gao Y,Tian M,Li N,Hao S,Zeng X.Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells[J]. Cancer Lett. 2005, 229(1):123 -126.
42. Parish CR, Freeman C,Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro assays for angiogenesis and heparanase activity[J].Cancer Res.1999;59 (14):3433-3441
43. Nasser NJ,Sarig G,Brenner B,Nevo E,Goldshmidt O,Zcharia E,Li JP,Vlodavsky I.Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin[J].J Thromb Haemost. 2006;4(3):560-565
44. Thodiyil P, Kakkar AK.Can low-molecularweight heparins improve outcome in patients with cancer?[J]. Cancer Treat Rev. 2002;28(3): 151-155
45. Bar-Ner M,Eldor A,Wasserman L,Matzner Y,Cohen IR,Fuks Z,Vlodavsky I.Inhibition of heparanase-mediated degradation of extracellularmatrix heparan sulfate by non-anticoagulant heparinspecies[J]. Blood.1987;70(6):551-557
46. Parish CR,Coombe DR,Jakobsen KB,Bennett FA,Underwood PA.Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases[J]. Int J Cancer. 1987;40(4):511-518
47. Nakajima M,Irimura T,Nicolson GL.Heparanases and tumor metastasis[J].J Cell Biochem. 1988;36(2):157-167
48. Vlodavsky I,Mohsen M,Lider O,Svahn CM,Ekre HP,Vigoda M,Ishai-Michaeli R,Peretz T. Inhibition of tumor metastasis by heparanase inhibiting species of Heparin [J]. Invasion Metastasis. 1994; 14(1-6):290-302
49. Edovitsky E,Elkin M,Zcharia E,Peretz T,Vlodavsky I.Heparanase gene silencing, tumor invasiveness, angiogenesis,and metastasis [J]. J Natl Cancer Inst. 2004;96(16): 1219-1230
50. Borsig L.Antimetastatic activities of modified heparins: Selectin inhibition by heparin attenuates [J]. Seminars in thrombosis and hemostasis.2007 33(5):540-546
51. Dirk Simonis,Katrin Christ,Susanne Alban,Gerd Bendas.Affinity and Kinetics of Different Heparins Binding to P- and L-Selectin[J]. Semin Thromb Hemost. 2007; 33 (5):534-539
52. Fan SQ,Qin LY,Cai JL,Zhu GY,Bin X,Yan HS.Effect of heparin on production of basic fibroblast growth factor and transforming growth factor-betal by human normal skin and hyperplastic scar fibroblasts. Burn Care&Research.2007;28(5):734-741
53. Yu YQ,Gu ST, Huang H,Wen TQ.Combination of BFGF,heparin and laminin induce the generation of dopaminergic neurons from rat neural stem cells both in vitro and in vivo. Neurological Sciences.2007 ;255(1-2)81 -86
54. Lee JS,Go DH, Bae JW,Lee SJ,Park KD.Heparin conjugated polymeric micelle for long-terin delivery of basic fibroblat growth factor.Controlled Release.2007;117(2): 204-209
55. Pike DB,Cai SS,Pomraning KR,Firpo MA,Fisher RJ,Shu XZ,Prestwich GD,Peattie RA. Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and BFGF. Biomaterials. 2006; 27 (30):5242-5251
56. Krilleke D,DeErkenez Z ,Schubert W,Giri I,Robinson GS,Ng YS,Shima DT. Molecular mapping and functional characterization of the VEGF164 heparin-binding domain. BIOLOGICAL CHEMISTRY .2007;282 (38): 28045-28056
57. Springer ML ,Banfi A,Ye JQ,Degenfeld G,Kraft PE,Saini SA,Kpasi NK,Blau HM. Localization of vascular response to VEGF is not dependent on heparin binding. Faseb Journal.2007; 21 (9): 2074-2085
58. Begum S,Zhang Y,Shintani T,Toratani S,Sat JD,Okamoto T. Immunohistochemical expression of heparin-binding protein 17/fibroblast growth factor-binding protein-1 (HBp17/FGFBP-1) as an angiogenic factor in head and neck tumorigenesis. Oncology Reports .2007,17 (3): 591-596
59. Pufe T,Groth G,Goldring MB,Tillmann B,Mentlein R. Effects of pleiotrophin, a heparin-binding growth factor,on human primary and immortalized chondrocytes. Osteoarthritis and Cartilage.2007; 15(2): 155-162
60. Cohen I,Pappo O,Elkin M,San T,Bar Shavit R,Hazan R,Peretz T,Vlodavsky I, Abramovitch R.Heparanase promotes growth,angiogenesis and survival of primary breast tumors [J].Int J Cancer .2006;118(7):1609-1617
61. Vlodavsky I,Abboud Jarrous G,Elkin M,Naggi A,Casu B,Sasisekharan R, Ilan N.The impact of heparanase and heparin on cancer metastasis and angiogenesis [J].Pathophysiol Haemost Thromb .2006;35(1-2):116-127
62. Ferro V,Dredge K,Liu,LG,Hammond E,Bytheway L,Li CP,Johnstone K,Karoli T,Davis K,Copeman E,Biotech B,Gautam A.PI-88 and novel heparan sulfate mimetics inhibit angiogenesis[J].Seminars in thrombosis and hemostasis.2007;33(5):557-562
63. Karpatkin S,Pearlstein E,Ambrogio C,Coller BS.Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest. 1988;81 (4): 1012-1019
64. Nieswandt B,Hafner M,Echtenacher B,Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets [J]. Cancer Res . 1999;59(6): 1295-1300
65. Sciumbata T,Caretto P,Pirovano P,Pozzi P,Cremonesi P,Galimberti G,Leoni F,Marcucci F. Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival [J]. Invasion Metastasis. 1996;16(3):132-143
66. Laubli H,Stevenson JL,Varki A,Varki NM,Borsig L.L-selectin facilitation of metastasis involves temporal induction of fut7-dependent ligands at sites of tumor cell arrest [J]. Cancer Res.2006;66(3): 1536-1542
67. Parish CR,Freeman C.Brown KJ,Francis DJ,Cowden WB.Identification of sulfated oligosaccharide-based inhibitors of tumor growth and metastasis using novel in vitro asssays for angiogenesis and heparanase activity [J].Cancer Res.1999;59(14):3433-41
68. Chen PJ,Lee PH,Lin DY.Novel heapranase inhibitor PI-88 extends disease free survival in a randomized phase II adjuvant clinical trial in patients with hepatocellular carcinoma(HCC) after curative resection [J]. J Hepatology.2007 ;46( Suppl 1): S293
69. Smorenburg SM,Van Noorden CJ.The complex efects of heparins on cancer progression and metastasis in experimental studies[J] .Pharmacol Rev.2001;53(1):93-105
70. Tyrrell DJ,Horne AP,Holme KR,Preuss JM,Page CP.Heparin in inflammation:Potential therapeutic applications beyond anticoagulation[J].Adv Pharmacol.1999;46: 151-208
71. Vlodavsky I, Miao HQ, Medalion B, Danagher P, Ron D. Involvement of heparan sulfate and related molecules in sequestration and growth promoting activity of fibrolast growth factor [J].Cancer Metastasis Rev.1996;15(2):177-186
72. Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini Guatta Z, Elkin M, Peretz T, Friedmann Y. Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development[J].Semin Cancer Biol,2002; 12(2): 121-129
73. Pross M, Lippert H, Misselwitz F, Nestler G, Kruger S, Langer H, Halangk W, Schulz HU. Low-Molecular weight Heparin (reviparin) dimishes tunlor cell adhesion and invasion in vitro, and decreases intraperitoneal growth of colonadeno-carcinoma cells in rats after laparoscopy[J]. Thromb Res.2003;110(4):210-215